Log in

NASDAQ:XBITXBiotech Stock Price, Forecast & News

-0.30 (-2.13 %)
(As of 06/2/2020 04:00 PM ET)
Today's Range
Now: $13.81
50-Day Range
MA: $14.42
52-Week Range
Now: $13.81
Volume130,589 shs
Average Volume618,489 shs
Market Capitalization$398.45 million
P/E RatioN/A
Dividend YieldN/A
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection and influenza diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Read More
XBiotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:XBIT



Sales & Book Value

Annual SalesN/A
Cash Flow$16.06 per share
Book Value$18.20 per share


Net Income$668.63 million


Market Cap$398.45 million
Next Earnings Date6/4/2020 (Estimated)

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.

XBiotech (NASDAQ:XBIT) Frequently Asked Questions

How has XBiotech's stock been impacted by COVID-19 (Coronavirus)?

XBiotech's stock was trading at $10.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XBIT shares have increased by 28.8% and is now trading at $13.81. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of XBiotech?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XBiotech.

When is XBiotech's next earnings date?

XBiotech is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for XBiotech.

How were XBiotech's earnings last quarter?

XBiotech Inc (NASDAQ:XBIT) released its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.15). View XBiotech's earnings history.

What price target have analysts set for XBIT?

2 Wall Street analysts have issued 12 month target prices for XBiotech's shares. Their forecasts range from $18.00 to $28.00. On average, they anticipate XBiotech's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 66.5% from the stock's current price. View analysts' price targets for XBiotech.

Has XBiotech been receiving favorable news coverage?

Media headlines about XBIT stock have been trending neutral recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. XBiotech earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutXBiotech.

Are investors shorting XBiotech?

XBiotech saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 2,220,000 shares, a decrease of 7.5% from the April 30th total of 2,400,000 shares. Based on an average trading volume of 513,200 shares, the days-to-cover ratio is currently 4.3 days. Approximately 16.2% of the shares of the company are sold short. View XBiotech's Current Options Chain.

Who are some of XBiotech's key competitors?

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Cidara Therapeutics (CDTX), Micron Technology (MU), Novavax (NVAX), Ocular Therapeutix (OCUL), Sanofi (SNY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Who are XBiotech's key executives?

XBiotech's management team includes the following people:
  • Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
  • Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
  • Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
  • Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board

When did XBiotech IPO?

(XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Who are XBiotech's major shareholders?

XBiotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.47%), Geode Capital Management LLC (0.96%), State Street Corp (0.92%), Jane Street Group LLC (0.49%), Russell Investments Group Ltd. (0.36%) and Nuveen Asset Management LLC (0.21%). Company insiders that own XBiotech stock include Fondation Rennes, Street Financial SA Bay, W Thorpe Mckenzie and W Thorpe Mckenzie. View institutional ownership trends for XBiotech.

Which institutional investors are selling XBiotech stock?

XBIT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Geode Capital Management LLC, Alps Advisors Inc., Squarepoint Ops LLC, Bank of New York Mellon Corp, Morgan Stanley, and Nuveen Asset Management LLC. View insider buying and selling activity for XBiotech.

Which institutional investors are buying XBiotech stock?

XBIT stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Balyasny Asset Management LLC, Russell Investments Group Ltd., Paloma Partners Management Co, Alliancebernstein L.P., AQR Capital Management LLC, BNP Paribas Arbitrage SA, and Meeder Asset Management Inc.. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes, and W Thorpe Mckenzie. View insider buying and selling activity for XBiotech.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $13.81.

How big of a company is XBiotech?

XBiotech has a market capitalization of $398.45 million. XBiotech employs 56 workers across the globe.

What is XBiotech's official website?

The official website for XBiotech is www.xbiotech.com.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.